World News – GB – Today is the perfect moment to buy cheap UK shares in ISA to retire early

German and American pharmaceutical companies have declared their vaccine candidate more than 90% effective in preventing COVID-19

I have spent most of my investing life looking for opportunities to buy cheap shares in the UK I think it makes sense to buy FTSE 100 and FTSE 250 stocks after the markets crash and trade major stocks at bargain prices It is a great opportunity to build the wealth you need to get rich and retire early

p>

The problem is that no one can accurately predict when the markets will collapse. It is impossible to predict stock price movements. If you stop at the perfect opportunity to buy cheap UK shares, you may not invest at all

Last week gave a good example of this. The US presidential election was a mammoth political event that had the potential to destabilize stock markets, especially if the outcome was severely disputed. Well, there was a dispute, and what happened? Investors hoping for an opportunity to buy cheap UK shares have found that it has become more expensive instead

Instead of crashing, markets jumped The FTSE 100 ended the week up nearly 6%. Why? Because investors liked the outcome, they were concerned that Democratic candidate Joe Biden’s program to increase corporate taxes, regulate technology, and the federal minimum wage would affect the company’s profits. However, as Republicans prepare to retain control of the Senate, the most drastic measures will likely be curtailed. / p>

This morning, the FTSE 100 has jumped 1% again 5%, and stands at exactly 6000. At the time of writing it was your chance to buy cheap shares in the UK last week, when it crossed 5,500 it has risen 9% since then

If you miss it, I won’t worry too much. Despite the recovery in recent days, I think many UK stock prices are still cheap The FTSE 100 has fallen about 20% since the start of the year, so you have a chance to buy here now there are major UK companies Trade at discounted prices everywhere

Of course, you can delay waiting for it until it gets cheaper. The stock market could collapse again, for example, due to Brexit, which is another huge political event that has the potential to move the markets. However, I would not recommend spending the next few weeks in Waiting for this to happen

First, I think there is still a fair chance of sealing a deal Second, nobody can say for sure how the markets will react

As we have seen in the US, investors have a troublesome habit of treating good news as bad, bad news as good. For example, if there is no Brexit deal and the British pound is disrupted, the FTSE 100 may rise and so Because companies listed on the index make three quarters of their profits abroad, which will be more valuable when converted back into a weaker British pound.

So don’t hold back hope that Brexit will bring cheap UK equity shares as always, the best time to buy stocks is today ideally at ISA, for tax-free income and capital growth that’s better I know how to fund early retirement

The post today is the perfect moment to buy cheap UK shares at ISA to retire early first appeared on The Motley Fool UK

How do I invest £ 200 a month in UK stocks to achieve passive income of £ 12,000 for life

The FTSE 100 Index fell to its lowest in six months. I will buy these FTSE 100 stocks now

Harvey Jones has no position in any of the aforementioned stocks Motley Fool UK does not have a position in any of the aforementioned stocks The opinions expressed about the companies mentioned in this article are the opinions of the author and therefore may differ from the official recommendations we provide in our subscription services. Like Share Advisor, Hidden Winners and Pro here at The Motley Fool, we believe that thinking through a variety of ideas makes us better investors

Carson attended an election night observation party last week at the White House. Both he and Mark Meadows, President Donald Trump’s chief of staff, were diagnosed after the event.

Taylor Wimpy, home maker on the FTSE 100, said on Monday that over the past few months he has approved deals to buy 70 sites through which he can develop real estate. Taylor Wimpy said today that as a result of the June capital increase, « we were confidently and resolutely re-entering the land market at the end of the second quarter and capitalizing on the increased opportunities » and said that since then it has agreed to terms and authorized about £ 826 million of total land purchases, which Includes 70 locations and about 14,500 pieces

Axio, a leading software-as-a-service in cyber risk management, today announced a strategic partnership with NFP, a leading insurance broker and advisor providing employee benefits, property and accidents, retirement, and individual solutions. NFP will deploy its new Axio platform, Axio360 QuickQuant, to expand the cybersecurity capabilities within the P&C division with a focus on the specialist needs of community banks

Tina Miller, Senior Vice President, Chief Financial Officer of Lithia Motors, Inc. (NYSE: LAD) is selected in the 2020 list of Women Leading in the North American Automobile Industry by Automotive News Every five years, Automotive News compiles a list of 100 Leading Women In the North American auto industry, with recognition of the most prominent female CEOs of automakers, suppliers, dealerships and vendors

At Verishop, we build a social trading platform with the mission of changing the way people shop. We launched in July 2019 to address two problems: to help users find DTC brands, independent brands and traditional retailers for all their lifestyle needs in one place; And to bring the best of social discoveries to shopping to create a more fun and inspiring place for brands to tell their stories and for our community to share their ideas

Participants in the American Film Market have been suspended this year due to restrictions imposed by the COVID-19 virus and the market that is heading by default These factors have led to major economic repercussions for Santa Monica, the coastal home of Konbab. There will be no strong breakfast at Cora’s Coffee Shoppe; Santa Monica’s 29 movie screens are dark; And the []

The new show starring James Taber, Rohan Campbell and Alexander Elliott begins December 4 on the broadcast service

Seung Hoon Che, KT IRO; Then Mr. Kyung-Keun Yoon, CFO, will present the earnings results and welcome your questions. This earnings release call is broadcast via our website, and you can follow the slides while listening to the call

With positive COVID-19 vaccine trial results emerging, governments and pharmaceutical companies face the next dreaded challenge: Convincing the world to vaccinate Public vaccine resistance has been discussed a lot this year, but the issue became very real on Monday when Pfizer and BioNTech announced that their candidate was relatively effective. Over 90% in large trials – raising a real shot on the horizon The World Health Organization estimates that about 70% of people must be inoculated to break transmission of the virus

CoreLogic® (NYSE: CLGX), a global leader in information, analytics and data-driven solutions, announced today that, after the successful implementation of the DigitalTax PlatformTM, Rushmore Loan Management Services LLC, Inc. Multifaceted residential mortgage mortgage services, able to demonstrate significant improvements in many important mortgage service efficiency metrics – which have enabled the innovative service provider to deliver an unparalleled customer experience.

2K and Gearbox Entertainment today relaunched the critically acclaimed Borderlands® 3, releasing new content, cosmetics, and retail releases, as well as an upgrade that improves the experience for next-generation consoles to watch the new trailer for Next- Level Mayhem, please click here, and for the new Season Pass 2 trailer, please click here

Real Estate Portfolio: € 974 million: 9% growth or € 81 million Return: increase in value due to increased revenue in logistics real estate in the Netherlands from 28 bpEPRA EPS: € 1,18 (€ 1, 46 Q3 2019, respectively) € 1,26 excluding Medtronic (EPRA NAV: € 21,89 per share (€ 21,79 on December 31, 2019)) Occupancy rate: 92% (93% as of December 31, 2019) Limited debt ratio: 43% (39% in 31 December 2019)) average interest rate on financing: 2.0% (2.2% Q3 2019) Total expected dividends per share for 2020: € 1.53 at the same level for 2019 projected EPRA earnings for 2020 based on Current projections: Between € 1.57 and 1,6221% of buildings are certified at least as a solid foundation of BREEAM. “Very good” due to activities in two divisions of real estate, sectoral spread of tenants, adequate financing capacity and strong balance sheet
Attached

Progress Statement Third Quarter 2020

VALLOUREC is a French limited liability company (société anonyme) with a board of directors and a supervisory board with a capital of 228,993 euros 88.Registered office: 27, avenue du Général Leclerc, 92100 Boulogne-Billancourt, France is registered with the Trade and Companies Registry of Nanterre under No. 552 142200 Boulogne-Billancourt, 9 November 2020 Monthly information related to the total number of voting rights and shares that include the capital share Article L 233-8-II of the Commercial Code and Article 223-16 of the General Regulations for Registered Financiers (AMF) Date Total number of shares outstanding Number the total theoretical voting rights * the total number of net voting rights October 31 202 011 44,969,411,809 92,911,808 September 84 830 202 011 449 69,411,809 87,711,808 79 631 August 202 011 449 69,411,792 3171179123631 July 202 011 449 69,411,792 29,111,791 21030 June 202 011 449 69,411,792 4871179135231 May 202 011 449 69,410,712,799,811 May 202 011 449 69,410,712,799,811 April 20531 March 2020457987 760467212665466689 16229 February 2020457987 760470490 4314699692831 January 2020457987 760470448 503469925 00031 December 2019457987 760470435 81246991230930 November 2019457987 760470 0431760 September 2019457987 76047037385746985035431 August 2019457987 760 470 365 86,146,984,235,831 July 2019457987 760 470 354 599 469 831 09 630 June 2019457987 7604 70370 May 96,046,984,281,431 2019457987 760 470 352 202 469 824 05 630 April 2019457987 760 470 352 409 469 717 89231 March 2019457987 760 470 318 361 468 612 08 928 February 2019457987 760 470 289 887 469 58,384,871,997,470 December 2018 184 470 195 14530 November 2018457987 760470207 119470116 08031 October 2018457987 760470207 002 470 115 September 96 330 2018457987 760 470 205 29,847,011,425,931 August 2018457987 760 470 204 668 470 113 62 931 July 2018457987 760 470 202 926 470 2018 77 431 May 2018457987 760 470 062 108 469 963 51 530 April 2018457987 760 470 063 0324699643931 March 2018457987 760 469 717 314,469,544,471,728 February 2018457987 760 469 607 83,246,943,523,531 January 2018457987 760 469 609 4807746 43 931 December 2018457987 760469 717 2017451238 005462770 922460117 31531 October 2017451238 005462753 994460100 38730 September 2017451238 005462 75 5 41,546,010,179,831 August 2,017,451,238 005 462 748 646 460 093 11631 July 2,017,451,238 005 462 748 766 460 084 16830 June 2,017,451,238 005 462 821 248 460 150 May 91 931 2,017,451,238 005 462 778 752 460 108 34330 April 201745123800560260777780 March 20,174,512,384,460 106 42 928 February 2,017,451,238 005 462 721 070 459 805 78 431 January 2,017,451,238 005 462 221 497 459 828 68131 December 2,016,451,238 005 462 720 629 459 882 78 314 December 2016451238 005462 582 247459 74439130 November 20164443528449440944439130 November 20164443528449440 September 2,016,444,638 049 455 984 25,645,346,797,431 August 2,016,444,638 049 455 986 535 453 695 22131 July 2,016,444,638 049 455 983 266 453 736 90230 June 2,016,444,638 049 455 981 777 453 882 46 720 June 2016444 638 04945592433924 May 2016444 638 May 049 455 963 072 484 394 405 623 392 511 28 930 April 2,016,135,688 432 147 021 736 145 132 39031 March 2016135688 432147015 827145 117 25029 February 2016 135688 432146951 002144 832 00231 January 2016 135688 432146945 75614482670231 December 2015135688 432146949 907144880 85330 November 2015133888 435 144901 125142832 035 * Theoretical, (or total rights used) to calculate the boundary override: Includes voting rights that have been stripped of non-voting shares (shares subject to special control, liquidity contract, etc.) Vallourec’s Bylaws contain a provision imposing an obligation to declare exceeding limits in addition to those relating to statutory thresholds This information is also available on the Vallourec website under the heading « Organized Information »: https://www.valourec.com / en / hub-finance / informations-reglementees
Attached

2020_11_09_ Voting Rights for Monthly Information

Big data specialist’s share price is down more than 15% despite strong third-quarter results.

Capital Disclosure and Pending Voting Rights as of October 31, 2020 (in accordance with Article L.233-8 II of the French Commercial Code and Articles 221-1 and 223-16 of the General Regulations for Registered Financiers) Charenton-le-Pont, France (9 November 2020 – 6:00 pm) – As of October 31, 2020, suspended shares and voting rights are suspended For EssilorLuxottica, the world leader in designing, manufacturing and distributing lenses, frames, and eye sunglasses as shown below October 31, 2020 Outstanding Shares 438,611,3461 Number of Real Voting Rights (excluding Treasury Shares) 436,279,928 Theoretical Number of Voting Rights (Including It should be noted that voting rights are limited to 31%, applicable to any shareholder, in accordance with the formula contained in Article 23 of EssilorLuxottica’s bylaws 2 For more information, please refer to the prospectus that obtained Visa No. 18-460 from the Arab Monetary Fund on September 28, 2018 and its securities appendix that obtained Visa No. 18-494 from AMF on October 23, 2018, available at www. EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and eyeglasses Ararat Solar was founded in 2018, and its mission is to help people around the world see more, be more and live life to the fullest by meeting the needs of advanced vision and aspirations of their personal style The company combines the complementary expertise of two industry leaders, one of them in Advanced lens technology and the other in the iconic eyeglass industry, to set new industry standards for eye care and consumer experience around influential eyewear brands including Ray-Ban and Oakley, lens technology brands including Varilux® and Transitions®, and global retail brands including In that Sunglass Hut and LensCrafters are part of the EssilorLuxottica family in 2019 EssilorLuxottica had more than 150000 employees and consolidated revenues of € 17 4 billion; EssilorLuxottica is traded on the Euronext Paris market and is listed on the Euro Stoxx 50 and CAC 40 indices and symbols: ISIN: FR0000121667; Reuters: ESLX PA; Bloomberg: EL: FP Contacts EssilorLuxottica Investor Relations (Charenton-le-Pont) Phone: 33 1 49 77 42 16 (Milan) Phone: 39 (02) 8633 4870 Email: ir @ essilorluxotticacomEssilorLuxottica Corporate Communications / Media Relations (Charenton- (le-Pont) Tel: 33 1 49 77 45 02 (Milan) Tel: 39 (02) 8633 4470 Email: media @ essilorluxottica com 1 Including 24,693 shares that were delivered but not yet registered 2 EssilorLuxottica regulations are available on the company’s website Within the Governance / Publications section or by clicking here
Attached

Download the PDF version of the newsletter

FireMon, the leader in network security policy management that provides visibility, control, agility, and automation for the enterprise cloud and hybrid network infrastructure, is pleased to announce that CRN®, a trademark of The Channel Company, has selected FireMon as one of the nominees at the CRN Tech Awards Innovator 2020 FireMon honored for FireMon Automation in the Security Category

Will the hordes of TV viewers who use televisions remotely begin to think of a receiver or broadband hub as some kind of shopping cart? NBCUniversal has partnered with PayPal that says it will make the relatively new concept of purchasing items suggested by TV shows easier and faster, as part of a growing offering by the company-owned Comcast []

Presentations Focusing on Myeloid Cells and the Signal « Don’t Eat Me » as a New Emerging Track of Interest in Immuno-oncology, Nantes, France, November 09, 2020 (GLOBE NEWSWIRE) – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) was invited to present An update on R&D’s programs in immuno-oncology at several dedicated international conferences in October and November The company’s wide presence in scientific cancer research events underlines its expertise in the highly attractive field of myeloid and macrophage, which have been identified as weak predictive factors in oncology and escape mechanisms Immunotherapy for Cancer Immunotherapies Presentation Details OSE Immunotherapeutics SITC: SITC (Association for Cancer Immunotherapeutics) Annual Meeting, 10-14 November 2020 Audio Slide Poster: “CLEC-1 is a new myeloid immunity checkpoint for cancer immunotherapy that limits the phagocytosis of cancer cells and synergizes With Antibodies Targeting Tumors Abstract: # 212 Showtime: Thursday, November 12, 4: 50-5: 20 AM ET and Saturday November 14, from 1-1: 30 AM will be shown ESTPosters Posters Starting 8 um on Monday November 9, until the virtual SITC poster hall closes on December 31, 2020, a presentation of the future of the novel « Don’t Eat Me » CLEC-1, identified in collaboration with Dr. Elise Chifolo and the University of Nantes Hospital team, as a goal New for the myeloid immune checkpoint for cancer immunotherapy similar to the SIRPα / CD47 pathway, the CLEC1 / CLEC1-Ligand pathway inhibits macrophage phagocytosis and antigen presentation by dendritic cells CLEC-1 ligand differentiates from CD47 as expressed by cancer cells under stress conditions, particularly when combined With cytotoxic chemotherapy and immunology, CLEC-1 monoclonal antibody developed by OSE triggers this inhibition and works synergistically with commercial antibodies targeting tumor antigens Additional presentations details at Immuno-oncology conferences: Summit of Targeted Macrophage Therapies, 27-29 Oct 2020, Talk about “Don’t eat me. Reference to targets as new immune checkpoint inhibitors: SIRPa validated and new CLEC-1 targets” CD47 / SIRPα Summit, 4-5 November 2020 Public Lecture: “P The primary biology behind alternative SIRP homologues & An overview of the OSE Immunotherapeutics approach ‘Presentation of R&D studies and their findings focusing on interest in’ don’t eat me ‘receptor blockade as a new emerging pathway of interest in immuno-oncology characterized localized and preclinical study data conducted on rodents In vivo and in vivo extra-human models the efficacy and mechanism of action of BI 765063, formerly known as OSE-172, which is the first selective antibody to « do not eat me » signals mediated by SIRPα The R&D team from OSE identified a SIRPα-mediated « do not find me » mechanism of action that reflects the mechanism of action. A major resistance and escape to immunotherapy called « T-cell exclusion » About OSE ImmunotherapeuticsOSE Immunotherapeutics is an integrated biotechnology company focused on developing therapies and establishing partnerships to control the immune system for immune tumors and autoimmune diseases. The company’s Immunology R&D platform focuses on three areas: Immunization Based on T cells, immuno-oncology (focus on spinal cord targets), and pain Subjective mildness, and & inflammation Its first-in-class balanced medical and preclinical portfolio features a diverse risk profile: Tedopi® Vaccine Platform (an innovative combination of new endoscopes): the company’s most advanced product; Positive results of Step 1 of a Phase 3 trial (Atalante 1) in failure of a post-checkpoint inhibitor for non-small cell lung cancer in stage II pancreatic cancer (TEDOPaM, sponsor GERCOR) in monotherapy and in combination with the checkpoint inhibitor Opdivo®CoVepiT: preventive vaccine Against COVID-19, developed using new enhanced SARS-CoV-2 episodes positive preclinical and ex vivo human results in August 2020, clinical trials are expected to begin in the first quarter of 2021 on Immuno-Oncology Platform BI 765063 (OSE). -172, anti-SIRPα mAb): developed in partnership with Boehringer Ingelheim; Stage 1 myeloid barrier inhibitor in advanced solid tumors CLEC-1 (new target for myeloid checkpoint): identification of the mAb antagonist of CLEC-1 that blocks the « don’t eat me » signal that increases phagocytosis by macrophages and antigen capture by BiCKI® : A bispecific fusion protein platform built on the main anti-PD-1 backbone component (OSE-279) along with novel immunotherapy targets; Second generation PD- (L) 1 inhibitors to increase anti-tumor efficacy of autoimmune system and FR104 (anti-CD28 monoclonal antibody): positive first-stage results; OSE-127 (humanized monoclonal antibody targeting the IL-7 receptor): developed in partnership with Servier; Positive results for the first stage; Two independent phases 2 planned in ulcerative colitis (OSE patron) and Sjogren’s syndrome (Servier’s patron) to start in the fourth quarter of 2020OSE-230 (ChemR23 agonist mAb): a first-class therapeutic agent with the ability to resolve chronic inflammation by pushing in affected tissues To Tissue Safety In view of the COVID-19 crisis, the backlog of new patients in the TEDOPaM clinical trial has been temporarily suspended and the start schedules for both OSE-127 Phase II trials could be affected over the coming months For more information: Click and follow us on Twitter and LinkedInhttps: // twitter com / OSEIMMUNO https: // www Linkedin com / company / 10929673 Contacts OSE ImmunotherapeuticsSylvie DétrySylvie Dettre @ ose-immunocom 33153198757 French media: FP2COM Florence Portejouportjoy @ fp2com fr 33607768283U Media Communications dar: lifeS386 lifesciadvisorscom 41 79367 6254 Forward-looking statements This press release contains information and express statements or statements. Monia can be considered information and forward-looking statements regarding the environment of the Immunotherapeutics operating system. It does not constitute historical facts. This information and data include financial projections that are based on some assumptions and evaluations made by OSE Immunotherapeutics management in light of its experience and perception of historical trends, current economic and industrial conditions, expected future developments and other factors. Believes appropriate These forward-looking statements include phrases that usually use subjunctive verbs and contain verbs such as “expect,” “expect,” “believe,” “aim,” “plan,” or “estimate” and their inflections, conjugations, and words of similar significance notwithstanding. The OSE Immunotherapies Department believes that the data and forward-looking information are reasonable, however Immunotherapeutics and other investors are warned that completion of these expectations is inherently subject to various risks, known or not, and uncertainties difficult to predict and generally outside the scope of Controlling the immune system environment These risks may cause different results and actual developments Materially as expressed, implied or expected in the forward-looking statements These risks include those discussed or identified in the public filings that OSE Immunotherapeutics has filed with AMF These forward-looking statements are not guarantees of future performance This press release contains only brief information and must be read with the extensive registration document for OSE Immunotherapeutics filed with AMF on April 15, 2020 Other than as required by applicable law, Immunotherapeutics, including the annual financial report for the fiscal year 2019, available on the OSE Immunotherapeutics website, issues this press release on the date of this statement and does not undertake any obligation to update or review information or forward-looking statements. / p>

Stocks, Stock Market, FTSE 100 Index, Financing, Singles Savings Account, Participation, The Motley Fool